Jefferies Financial Group Inc. grew its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 217.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,000 shares of the life sciences company’s stock after buying an additional 5,478 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Illumina were worth $2,189,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Illinois Municipal Retirement Fund boosted its stake in shares of Illumina by 6.8% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 115,293 shares of the life sciences company’s stock worth $31,553,000 after buying an additional 7,327 shares during the last quarter. Lido Advisors LLC grew its holdings in shares of Illumina by 61.5% in the third quarter. Lido Advisors LLC now owns 7,084 shares of the life sciences company’s stock worth $1,939,000 after acquiring an additional 2,698 shares during the period. Keybank National Association OH increased its position in Illumina by 1.5% during the third quarter. Keybank National Association OH now owns 376,809 shares of the life sciences company’s stock valued at $103,125,000 after acquiring an additional 5,682 shares during the last quarter. 71 West Capital Partners purchased a new stake in Illumina during the third quarter valued at $412,000. Finally, Gryphon Financial Partners LLC bought a new position in Illumina in the third quarter valued at about $252,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Illumina
In other news, CAO Scott Ericksen sold 267 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $217.76, for a total value of $58,141.92. Following the transaction, the chief accounting officer owned 14,029 shares of the company’s stock, valued at $3,054,955.04. This trade represents a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 98,833 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total value of $21,433,912.71. Following the completion of the transaction, the director directly owned 208,826 shares in the company, valued at $45,288,094.62. This trade represents a 32.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 1,881,899 shares of company stock valued at $415,905,954. Company insiders own 2.90% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on ILMN shares. Canaccord Genuity Group increased their target price on Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a report on Monday, October 19th. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and boosted their price target for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. JPMorgan Chase & Co. cut their price target on Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Stephens lowered shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price target for the company. in a research report on Friday, October 23rd. Finally, Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average price target of $244.24.
View Our Latest Research Report on ILMN
Recent Illumina Headlines
Here are a few of the latest headlines about ILMN:
- Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook
- Neutral Sentiment: Chief Accounting Officer Scott Ericksen sold 267 shares under a pre-arranged Rule 10b5-1 plan, a relatively small reduction in his holdings. SEC filing
- Negative Sentiment: Director Keith Meister sold 280,091 shares for approximately $61.1 million across November 9–11, cutting his direct stake substantially. The scale of the sales could concern investors, although he retained a sizable holding. SEC filing
Illumina Stock Performance
NASDAQ:ILMN opened at $207.01 on Monday. Illumina, Inc. has a one year low of $112.65 and a one year high of $309.35. The business has a fifty day moving average price of $249.02 and a 200-day moving average price of $179.64. The firm has a market capitalization of $31.30 billion, a price-to-earnings ratio of 35.63, a price-to-earnings-growth ratio of 2.81 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05.
Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. Illumina’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.34 earnings per share. Sell-side analysts forecast that Illumina, Inc. will post 5.43 EPS for the current year.
Illumina Company Profile
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
See Also
- Five stocks we like better than Illumina
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
